loading
前日終値:
$3.27
開ける:
$3.27
24時間の取引高:
1.44M
Relative Volume:
1.69
時価総額:
$660.74M
収益:
$12.99M
当期純損益:
$-74.39M
株価収益率:
-7.9545
EPS:
-0.44
ネットキャッシュフロー:
$-78.92M
1週間 パフォーマンス:
+6.71%
1か月 パフォーマンス:
+3.86%
6か月 パフォーマンス:
-8.62%
1年 パフォーマンス:
+35.66%
1日の値動き範囲:
Value
$3.26
$3.54
1週間の範囲:
Value
$3.20
$3.54
52週間の値動き範囲:
Value
$2.30
$4.725

Arbutus Biopharma Corp Stock (ABUS) Company Profile

Name
名前
Arbutus Biopharma Corp
Name
セクター
Healthcare (1166)
Name
電話
604-419-3200
Name
住所
701 VETERANS CIRCLE, WARMINSTER, PA
Name
職員
73
Name
Twitter
@arbutusbio
Name
次回の収益日
2025-03-26
Name
最新のSEC提出書
Name
ABUS's Discussions on Twitter

ABUS を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ABUS
Arbutus Biopharma Corp
3.50 660.74M 12.99M -74.39M -78.92M -0.44
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.69 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
637.36 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
589.15 35.93B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.46 34.75B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
267.39 28.24B 3.81B -644.79M -669.77M -6.24

Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2022-02-02 アップグレード Jefferies Hold → Buy
2021-02-25 開始されました Jefferies Hold
2020-12-17 開始されました H.C. Wainwright Buy
2020-07-27 再開されました JMP Securities Mkt Outperform
2020-07-24 ダウングレード Robert W. Baird Outperform → Neutral
2020-05-19 アップグレード Wedbush Neutral → Outperform
2020-03-06 アップグレード Chardan Capital Markets Neutral → Buy
2020-02-20 開始されました Robert W. Baird Outperform
2020-02-05 アップグレード JMP Securities Mkt Perform → Mkt Outperform
2019-10-07 繰り返されました B. Riley FBR Buy
2019-10-04 ダウングレード Chardan Capital Markets Buy → Neutral
2018-10-16 アップグレード B. Riley FBR Neutral → Buy
2018-10-15 アップグレード Wedbush Underperform → Neutral
2018-10-12 繰り返されました Chardan Capital Markets Buy
2018-07-06 ダウングレード B. Riley FBR, Inc. Buy → Neutral
2018-03-19 再開されました Chardan Capital Markets Buy
2018-03-19 ダウングレード Wedbush Outperform → Neutral
2018-01-05 開始されました B. Riley FBR, Inc. Buy
2017-04-04 アップグレード Chardan Capital Markets Neutral → Buy
2017-02-01 繰り返されました Wedbush Outperform
2016-12-13 ダウングレード Chardan Capital Markets Buy → Neutral
2016-11-30 アップグレード Chardan Capital Markets Neutral → Buy
すべてを表示

Arbutus Biopharma Corp (ABUS) 最新ニュース

pulisher
05:50 AM

Arbutus Biopharma (NASDAQ:ABUS) Rating Increased to Hold at StockNews.com - Defense World

05:50 AM
pulisher
Mar 28, 2025

Arbutus Biopharma Reports 2024 Financial Results and Strategic Updates - MyChesCo

Mar 28, 2025
pulisher
Mar 27, 2025

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

Arbutus Biopharma earnings beat by $0.02, revenue fell short of estimates - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Arbutus stock gains after 57% workforce cuts (ABUS:NASDAQ) - Seeking Alpha

Mar 27, 2025
pulisher
Mar 27, 2025

Was there any good news for Arbutus Biopharma Corp (ABUS) stock in the last session? - US Post News

Mar 27, 2025
pulisher
Mar 27, 2025

Arbutus Biopharma Corp reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025
pulisher
Mar 27, 2025

Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Arbutus Biopharma Announces 2024 Financial Results and Strategic Restructuring - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Charles Schwab Investment Management Inc. Acquires 9,955 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Mar 27, 2025
pulisher
Mar 20, 2025

Arbutus Biopharma Co-Founder Dr. Michael Sofia to Retire After a Storied Career in Antiviral Drug Discovery - MSN

Mar 20, 2025
pulisher
Mar 10, 2025

Reviewing Akari Therapeutics (NASDAQ:AKTX) and Arbutus Biopharma (NASDAQ:ABUS) - Defense World

Mar 10, 2025
pulisher
Mar 08, 2025

FY2025 Earnings Forecast for ABUS Issued By Chardan Capital - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

Are Arbutus Biopharma Corp’shares a good deal? - US Post News

Mar 07, 2025
pulisher
Mar 04, 2025

Moderna Faces MRNA Vax Patent Suits In Canada And Beyond - Law360

Mar 04, 2025
pulisher
Mar 03, 2025

Genevant Sciences and Arbutus Biopharma Initiate - GlobeNewswire

Mar 03, 2025
pulisher
Mar 03, 2025

Genevant Sciences and Arbutus Biopharma File International Lawsuits Against Moderna for Patent Infringement of Lipid Nanoparticle Technology - Nasdaq

Mar 03, 2025
pulisher
Mar 03, 2025

Can Arbutus Win Billions? Patent Fight Against Moderna's COVID Vaccine Goes Global - StockTitan

Mar 03, 2025
pulisher
Mar 03, 2025

Genevant and Arbutus File Global Patent Lawsuits Against Moderna - TipRanks

Mar 03, 2025
pulisher
Feb 28, 2025

Arbutus Biopharma (NASDAQ:ABUS) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

StockNews.com Downgrades Arbutus Biopharma (NASDAQ:ABUS) to Sell - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Brokers Issue Forecasts for ABUS FY2029 Earnings - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Brokers Set Expectations for ABUS FY2029 Earnings - Defense World

Feb 28, 2025
pulisher
Feb 27, 2025

Arbutus Biopharma (ABUS) Projected to Post Earnings on Thursday - Defense World

Feb 27, 2025
pulisher
Feb 26, 2025

Arbutus Biopharma (NASDAQ:ABUS) Lowered to “Sell” Rating by StockNews.com - Defense World

Feb 26, 2025
pulisher
Feb 26, 2025

Arbutus Biopharma Appoints Lindsay Androski as CEO Amid Leadership Restructuring - MyChesCo

Feb 26, 2025
pulisher
Feb 25, 2025

Lindsay Androski named CEO of Arbutus - BioCentury

Feb 25, 2025
pulisher
Feb 25, 2025

Arbutus Biopharma appoints new CEO and reshapes board - Investing.com

Feb 25, 2025
pulisher
Feb 25, 2025

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO - The Manila Times

Feb 25, 2025
pulisher
Feb 25, 2025

Hepatitis B Market to Reach New Heights in Growth by 2032, - openPR

Feb 25, 2025
pulisher
Feb 24, 2025

Arbutus Biopharma Corp expected to post a loss of 8 cents a shareEarnings Preview - TradingView

Feb 24, 2025
pulisher
Feb 20, 2025

Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So. - The Motley Fool

Feb 20, 2025
pulisher
Feb 20, 2025

Arbutus Biopharma's CFO David Hastings sells shares worth $72,826 - MSN

Feb 20, 2025
pulisher
Feb 12, 2025

The Hidden Gem in Nasdaq’s Under $5 Club: Is Arbutus Biopharma the Next Big Thing? - Jomfruland.net

Feb 12, 2025
pulisher
Feb 12, 2025

Is Arbutus Biopharma Corp. (ABUS) the Best Nasdaq Stock Under $5 to Buy? - MSN

Feb 12, 2025
pulisher
Feb 11, 2025

Ebola Virus Vaccine Market May See a Big Move| Arbutus Biopharma, BioCryst Pharmaceuticals - openPR

Feb 11, 2025
pulisher
Feb 11, 2025

10 Best Nasdaq Stocks Under $5 to Buy - Insider Monkey

Feb 11, 2025
pulisher
Feb 08, 2025

SG Americas Securities LLC Purchases 16,250 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Feb 08, 2025
pulisher
Feb 06, 2025

Arbutus Biopharma Corp (ABUS) Stock: A Look at the Monthly Trend - The News Heater

Feb 06, 2025
pulisher
Feb 05, 2025

Arbutus Biopharma's CFO David Hastings sells shares worth $72,826 By Investing.com - Investing.com South Africa

Feb 05, 2025
pulisher
Feb 05, 2025

Jefferies analysts upgrades a Buy rating for Arbutus Biopharma Corp (ABUS) - Knox Daily

Feb 05, 2025
pulisher
Feb 05, 2025

Arbutus Biopharma Executives Sell Shares to Cover Tax Obligations - TradingView

Feb 05, 2025
pulisher
Feb 04, 2025

Arbutus Biopharma Corp (ABUS) expanding its growth trajectory ahead - SETE News

Feb 04, 2025
pulisher
Feb 03, 2025

Morgan Stanley Reduces Stake in Arbutus Biopharma Corp - GuruFocus.com

Feb 03, 2025
pulisher
Jan 30, 2025

JPMorgan Chase & Co. Increases Stock Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Jan 30, 2025
pulisher
Jan 27, 2025

Ballentine Partners LLC Acquires New Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Jan 27, 2025
pulisher
Jan 27, 2025

Arbutus Biopharma Corp. to Host Earnings Call - ACCESS Newswire

Jan 27, 2025
pulisher
Jan 22, 2025

Arbutus Biopharma (NASDAQ:ABUS) Receives “Buy” Rating from HC Wainwright - Defense World

Jan 22, 2025
pulisher
Jan 21, 2025

Arbutus Biopharma (NASDAQ:ABUS) Receives "Buy" Rating from HC Wainwright - MarketBeat

Jan 21, 2025
pulisher
Jan 17, 2025

Arbutus Biopharma Sets Sights on Advancing HBV Cure in 2025 - MyChesCo

Jan 17, 2025
pulisher
Jan 16, 2025

Jim Cramer on Arbutus Biopharma Corporation (ABUS): ‘It Loses Money’ - Insider Monkey

Jan 16, 2025

Arbutus Biopharma Corp (ABUS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
大文字化:     |  ボリューム (24 時間):